ArticleCancers2022

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.

Ana López González et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.